{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:23:25Z","timestamp":1793201005124,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T00:00:00Z","timestamp":1412035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s11926-014-0457-0","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T15:54:17Z","timestamp":1412006057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The Role of Nitisinone in Tyrosine Pathway Disorders"],"prefix":"10.1007","volume":"16","author":[{"given":"Edward","family":"Lock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshminarayan R.","family":"Ranganath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Timmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,30]]},"reference":[{"key":"457_CR1","first-page":"73","volume":"2","author":"AE Garrod","year":"1908","unstructured":"Garrod AE. The Croonian lectures on inborn errors of metabolism. Lecture II. Alkaptonuria. Lancet. 1908;2:73\u20139.","journal-title":"Lancet"},{"key":"457_CR2","unstructured":"Michaely WJ, Kratz GW. Certain 2-(2-substituted benzoyl)-1,3-cyclohexanediones. 1986; European Patent Application 0135191."},{"key":"457_CR3","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1016\/j.bmc.2009.03.015","volume":"17","author":"R Beaudegnies","year":"2009","unstructured":"Beaudegnies R, Edmunds AJF, Frazer TEM, et al. Herbicidal 4-hydroxyphenylpyruvate dioxygenase inhibitors \u2013 a review of the triketone chemistry story from a Syngenta perspective. Bioorg Med Chem. 2009;17:4134\u201352.","journal-title":"Bioorg Med Chem"},{"key":"457_CR4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1006\/taap.1996.0310","volume":"141","author":"EA Lock","year":"1996","unstructured":"Lock EA, Gaskin P, Ellis MK, et al. Tissue distribution of 2-(2-nitro-4-trifluoromethyl benzoyl)-cyclohexane-1,3-dione ( NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol Appl Pharmacol. 1996;141:439\u201347.","journal-title":"Toxicol Appl Pharmacol"},{"key":"457_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.taap.2006.01.015","volume":"215","author":"EA Lock","year":"2006","unstructured":"Lock EA, Gaskin P, Ellis MK, et al. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethyl benzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury. Toxicol Appl Pharmacol. 2006;215:9\u201316.","journal-title":"Toxicol Appl Pharmacol"},{"key":"457_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/978-1-4615-1887-7_38","volume-title":"Ocular toxicology","author":"M Robinson","year":"1995","unstructured":"Robinson M. The corneal effects of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in the rat. In: Weisse I, Hockwin O, Green K, Tripathi RC, editors. Ocular toxicology. New York and London: Plenum Press; 1995. p. 327\u201334."},{"key":"457_CR7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0300-483X(99)00205-X","volume":"144","author":"EA Lock","year":"2000","unstructured":"Lock EA, Gaskin P, Ellis MK, et al. Tissue distribution of 2-(2-nitro-4-trifluoromethyl benzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse. Toxicology. 2000;144:179\u201387.","journal-title":"Toxicology"},{"key":"457_CR8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7164\/antibiotics.35.458","volume":"35","author":"S Koizumi","year":"1982","unstructured":"Koizumi S, Nagatsu T, Iinuma H, et al. Inhibition of phenyl hydroxylase, a pterin-requiring monooxygenase by oudenone and its derivatives. J Antibiot. 1982;35:458\u201362.","journal-title":"J Antibiot"},{"key":"457_CR9","first-page":"731","volume":"3","author":"MP Prisbylla","year":"1993","unstructured":"Prisbylla MP, Onisko BC, Shribbs JM, et al. The novel mechanism of action of the herbicidal triketones. Weeds. 1993;3:731\u20138.","journal-title":"Weeds"},{"key":"457_CR10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0076-6879(87)42021-1","volume":"142","author":"S Lindstedt","year":"1987","unstructured":"Lindstedt S, Odelhog B. 4-Hydroxyphenylpyruvate dioxygenase from human liver. Methods Enzymol. 1987;142:139\u201342.","journal-title":"Methods Enzymol"},{"key":"457_CR11","doi-asserted-by":"crossref","unstructured":"Moran GR. 4-Hydroxyphenylpyruvate dioxygenase. 2005;433:117-28.","DOI":"10.1016\/j.abb.2004.08.015"},{"key":"457_CR12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/taap.1995.1121","volume":"133","author":"MK Ellis","year":"1995","unstructured":"Ellis MK, Whitfield AC, Gowan LA, et al. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulphonylbenzoyl)-cyclohexane-1,3-dione. Toxicol Appl Pharmacol. 1995;133:12\u20139.","journal-title":"Toxicol Appl Pharmacol"},{"key":"457_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/taap.1998.8404","volume":"150","author":"EA Lock","year":"1998","unstructured":"Lock EA, Gaskin P, Ellis MK, et al. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinaemia, and the activity of enzymes involved in tyrosine catabolism in the rat. Toxicol Appl Pharmacol. 1998;150:125\u201332.","journal-title":"Toxicol Appl Pharmacol"},{"key":"457_CR14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0014-4835(73)90170-X","volume":"17","author":"LF Rich","year":"1973","unstructured":"Rich LF, Beard ME, Burns RP. Excess dietary tyrosine and corneal lesions. Exp Eye Res. 1973;17:87\u201397.","journal-title":"Exp Eye Res"},{"key":"457_CR15","first-page":"547","volume-title":"The metabolic basis of inherited disease","author":"LA Goldsmith","year":"1989","unstructured":"Goldsmith LA, Laberge C. Tyrosinaemia and related disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw-Hill; 1989. p. 547\u201362."},{"key":"457_CR16","first-page":"302","volume":"47","author":"M DeBraekeller","year":"1990","unstructured":"DeBraekeller M, Larochelle J. Genetic epidemiology of hereditary tyrosinaemia in Quebec and Saguenay-Lac-St- Jean. Am J Hum Genet. 1990;47:302\u20137.","journal-title":"Am J Hum Genet"},{"key":"457_CR17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(92)92685-9","volume":"340","author":"S Lindstedt","year":"1992","unstructured":"Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340:813\u20137.","journal-title":"Lancet"},{"key":"457_CR18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2012.05.022","volume":"107","author":"J Larochelle","year":"2012","unstructured":"Larochelle J, Alvarez F, Bussieres JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab. 2012;107:49\u201354. A recent review on the efficacy of nitisinone for the treatment of HT-1.","journal-title":"Mol Genet Metab"},{"key":"457_CR19","unstructured":"Bodeker. Zeitschrift fur Rationale Medicin. 1859;VII:130."},{"key":"457_CR20","first-page":"228","volume":"XV","author":"Wolkow","year":"1891","unstructured":"Wolkow, Baumann. Z Physiol Chem. 1891;XV:228.","journal-title":"Z Physiol Chem"},{"key":"457_CR21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0021-9258(18)70560-7","volume":"230","author":"BN Du La","year":"1958","unstructured":"La Du BN, Zannoni VG, Laster L, et al. The nature of the defect in tyrosine metabolism in alcaptonuria. J Biol Chem. 1958;230:251\u201360.","journal-title":"J Biol Chem"},{"key":"457_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ng1093-201","volume":"5","author":"MR Pollak","year":"1993","unstructured":"Pollak MR, Chou YH, Cerda JJ, et al. Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat Genet. 1993;5:201\u20134.","journal-title":"Nat Genet"},{"key":"457_CR23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0002-9343(63)90089-5","volume":"34","author":"WM O\u2019Brien","year":"1963","unstructured":"O\u2019Brien WM, La Du BN, Bunim JJ. Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: review of world literature (1584\u20131962). Am J Med. 1963;34:813\u201338.","journal-title":"Am J Med"},{"key":"457_CR24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1096-7192(02)00121-X","volume":"77","author":"WJ Introne","year":"2002","unstructured":"Introne WJ, Phornphutkul C, Bernardini I, et al. Exacerbation of the ochronosis of Alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab. 2002;77:136\u201342.","journal-title":"Mol Genet Metab"},{"key":"457_CR25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0304-4165(69)90068-3","volume":"177","author":"VG Zannoni","year":"1969","unstructured":"Zannoni VG, Lomtevas N, Goldfiner S. Oxidation of homogentisic acid to ochronotic pigment in connective tissue. Biochim Biophys Acta. 1969;177:94.","journal-title":"Biochim Biophys Acta"},{"key":"457_CR26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2559.2008.03000.x","volume":"53","author":"TR Helliwell","year":"2008","unstructured":"Helliwell TR, Gallagher JA, Ranganath LR. Alkaptonuria \u2013 a review of surgical and autopsy pathology. Histopathology. 2008;53:503\u201312.","journal-title":"Histopathology"},{"key":"457_CR27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1034\/j.1399-0004.2000.580115.x","volume":"58","author":"M Zibolen","year":"2000","unstructured":"Zibolen M, Srsnova K, Srsen S. Increased urolithiasis in patients with alkaptonuria in childhood. Clin Genet. 2000;58:79\u201380.","journal-title":"Clin Genet"},{"key":"457_CR28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10545-011-9374-9","volume":"34","author":"LR Ranganath","year":"2011","unstructured":"Ranganath LR, Cox TF. Natural history of Alkaptonuria revisited: analyses based on scoring systems. J Inherit Metab Dis. 2011;34:1141\u201351. A recent review describing the natural history of AKU.","journal-title":"J Inherit Metab Dis"},{"key":"457_CR29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02081762","volume":"3","author":"V Krizek","year":"1971","unstructured":"Krizek V. Urolithiasis and prostatolithiasis in alcaptonuria with ochronosis. Int Urol Nephrol. 1971;3:245\u201350.","journal-title":"Int Urol Nephrol"},{"key":"457_CR30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1302\/0301-620X.85B6.13662","volume":"85","author":"RV Manoj Kumar","year":"2003","unstructured":"Manoj Kumar RV, Rajasekaran S. Spontaneous tendon ruptures in Alkaptonuria. J Bone Joint Surg Br. 2003;85:883\u20136.","journal-title":"J Bone Joint Surg Br"},{"key":"457_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3121\/cmr.2.4.209","volume":"2","author":"AA Fisher","year":"2004","unstructured":"Fisher AA, Davis MW. Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review. Clin Med Res. 2004;2:209\u201315.","journal-title":"Clin Med Res"},{"key":"457_CR32","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1097\/BRS.0b013e31816046ea","volume":"33","author":"K Akeda","year":"2008","unstructured":"Akeda K, Kasai Y, Kawakita E, et al. Thoracic myelopathy with Alkaptonuria. Spine. 2008;33:E62\u20135.","journal-title":"Spine"},{"key":"457_CR33","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/art.30606","volume":"63","author":"AM Taylor","year":"2011","unstructured":"Taylor AM, Boyde A, Wilson PJ, et al. The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheum. 2011;63:3887\u201396. A recent review describing the process of AKU damage to cartilage.","journal-title":"Arthritis Rheum"},{"key":"457_CR34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1203\/00006450-198908000-00015","volume":"26","author":"JA Wolff","year":"1989","unstructured":"Wolff JA, Barshop B, Nyhan WL, et al. Effects of ascorbic acid in Alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res. 1989;26:140\u20134.","journal-title":"Pediatr Res"},{"key":"457_CR35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/jclinpath-2012-200877","volume":"66","author":"LR Ranganath","year":"2013","unstructured":"Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article) [Review]. J Clin Pathol. 2013;66:367\u201373. A recent review detailing current best practise for the clinical management of alkaptonuria.","journal-title":"J Clin Pathol"},{"key":"457_CR36","doi-asserted-by":"crossref","first-page":"d5155","DOI":"10.1136\/bmj.d5155","volume":"343","author":"S Laxon","year":"2011","unstructured":"Laxon S, Ranganath L, Timmis O. A patient\u2019s journey: living with Alkaptonuria. Br Med J. 2011;343:d5155.","journal-title":"Br Med J"},{"key":"457_CR37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2011.04.016","volume":"103","author":"WJ Introne","year":"2011","unstructured":"Introne WJ, Perry MB, Troendle J, et al. A 3-year randomized therapeutic trial of nitisinone in Alkaptonuria. Mol Genet Metab. 2011;103:307\u201314.","journal-title":"Mol Genet Metab"},{"key":"457_CR38","doi-asserted-by":"crossref","unstructured":"Stewart RM, Briggs MC, Jarvis JC, et al. Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report. JIMD Rep. 2014.","DOI":"10.1007\/8904_2014_307"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-014-0457-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-014-0457-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-014-0457-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T04:48:24Z","timestamp":1717390104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-014-0457-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,30]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s11926-014-0457-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,30]]},"article-number":"457"}}